Active targeting polymer micelle encapsulating drug, and pharmaceutical composition

• US 8,741,339 B2
• Filed: 07/29/2009
• Issued: 06/03/2014
• Est. Priority Date: 07/29/2008
• Status: Active Grant

• Current Assignee: NanoCarrier Co., Ltd.
• Original Assignee: Nonocarrier Company Limited
• Inventors: Kato, Yasuki, Harada, Mitsunori, Saito, Hiroyuki, Hayashi, Tatsuyuki
• Primary Examiner(s): Wax, Robert A
• Assistant Examiner(s): Tcherkasskaya, Olga V
• Application Number:
  US12/672,496
• Publication Number:
  US 20100221320A1
• Time in Patent Office: 1,770 Days
• Field of Search: None
• US Class Current: 424/451
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61K 47/642 the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
• CPC Class Codes: A61K 47/644 Transferrin, e.g. a lactoferrin or ovotransferrin
• CPC Class Codes: A61K 47/6845 the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
• CPC Class Codes: A61K 47/6849 the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
• CPC Class Codes: A61K 47/6905 the form being a colloid or an emulsion
• CPC Class Codes: A61K 47/6907 the form being a microemulsion, nanoemulsion or micelle
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

The present invention provides an active targeting polymer micelle encapsulating a drug, preventing an inappropriate release of a drug which may damage a normal cell. A polymer micelle 100 includes a backbone polymer unit 10 that has a target binding site 11 and a backbone polymer unit 20 that has a drug 14 and is free from the target binding site 11, such polymer units 10 and 20 being disposed in a radial arrangement in a state where the target binding site 11 is directed outward and the drug 14 is directed inward, in which: i) when the micelle is bound to a target 40 while maintaining the radial arrangement, the micelle is taken up into a cell 50 supplying the target 40 through endocytosis, and the drug 14 is released into the cell 50 by collapse of the radial arrangement in the cell 50; and ii) when the radial arrangement collapses in blood 60 before the micelle is bound to a target 40, the unit 20 is excreted through metabolism, to thereby prevent a normal cell from being damaged by the drug 14.

Claims

1. A polymer micelle encapsulating a drug comprising:

a polymer α

represented by the general formula I;

Z-A₁-B₁ 

 

(I); and

a polymer β

represented by the general formula II;

A₂-B₂(-D) 

 

(II)

where;

Z represents a residue of a compound having a target binding site;

A₁ and A₂ each independently represent a hydrophilic segment of a polyethylene glycol chain;

B₁ and B₂ each independently represent a hydrophobic segment of a polyamino acid chain; and

D represents the drug with the proviso that one or more copies of the drug is (are) respectively covalently bound to one or more side chains of the polyamino acid chain of the polymer β

, wherein when the polymer micelles collapse in blood, the polymer β

is excreted through metabolism, to thereby prevent a normal cell from being damaged by the drug.

2. The polymer micelle according to claim 1, wherein the polymer α

is represented by the following general formula I-a or I-b, and the polymer β

is represented by the following general formula II-a or II-b;

3. A pharmaceutical composition, comprising the polymer micelle according to claim 1 and a pharmaceutically acceptable carrier.

4. The polymer micelle according to claim 1, further comprising:

a polymer γ

represented by the general formula III;

A₃-B₃ 

 

(III);

where;

A₃ represents a hydrophilic segment of a polyethlene glycol chain, B₃ represents a hydrophobic segment of a polyamino acid chain, and the polymer γ

is free of the target binding site and the drug.

5. The polymer micelle according to claim 1, wherein the polymer micelle contains no free drug.

6. The polymer micelle according to claim 1, wherein the target binding site comprises transferrin and the drug is docetaxel.

7. The polymer micelle according to claim 1, wherein the polyamino acid chain of the polymer α

and the polymer β

are each respectively and individually selected from polyglutamic acid, polyaspartic acid, ester derivatives thereof, amide derivatives thereof and salts thereof.

8. The polymer micelle according to claim 2, wherein n₁ and n₂ are 70-350.

9. The polymer micelle according to claim 8, wherein n₁ and n₂ are 110-280 and m₁ and m₂ are 25-50.

10. The polymer micelle according to claim 9, wherein the polyamino acid chain of the polymer α

is comprised of poly(β

-benzyl-L-aspartate), and the polyamino acid chain of the polymer β

is comprised of poly(α

-glutamic acid).

11. The polymer micelle according to claim 10, wherein the polymer micelle contains no free drug.

12. The polymer micelle according to claim 10, wherein the target binding site comprises transferrin and the drug is docetaxel.

13. The polymer micelle according to claim 1, wherein the target binding site comprises an F(ab′

)₂ fragment and/or an Fab fragment.

14. The polymer micelle according to claim 1, wherein the drug is selected from the group consisting of a nucleic acid derivative, temsirolumus and everolimus.

15. The polymer micelle according to claim 14, wherein the drug is gemcitabine.

16. The polymer micelle according to claim 15, wherein the target binding site comprises an F(ab′

)₂ fragment and/or an Fab fragment.

17. The polymer micelle according to claim 1, wherein the drug is selected from the group consisting of epothilone A, epothilone B, epothilone C, epothilone D, and derivatives thereof.

18. The polymer micelle according to claim 17, wherein the drug is epothilone B.

19. The polymer micelle according to claim 18, wherein the target binding site comprises an F(ab′

)₂ fragment and/or an Fab fragment.

20. A method of treating human breast cancer, comprising:

administering a therapeutically effective amount of whole polymer micelles according to claim 1 to a patient in need thereof.

21. The polymer micelle according to claim 1, wherein the drug is bound to the polyamino acid chain via an ester bond or an amide bond.